Online inquiry

IVTScrip™ mRNA-Human Aminopeptidase-N, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK16053MR)

This product GTTS-WK16053MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the Aminopeptidase-N protein. This product can be used in Thecal cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001150.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 290
UniProt ID P15144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human Aminopeptidase-N, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK16053MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK28759MR IVTScrip™ mRNA-Human ATG4B, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ATG4B
GTTS-WK23322MR IVTScrip™ mRNA-Human ASPA, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASPA
GTTS-WK7492MR IVTScrip™ mRNA-Human AGBL4, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGBL4
GTTS-WK26423MR IVTScrip™ mRNA-Human APOBEC3G, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APOBEC3G
GTTS-WK9591MR IVTScrip™ mRNA-Human AGBL2, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGBL2
GTTS-WK9140MR IVTScrip™ mRNA-Human ACP5, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACP5
GTTS-WK17514MR IVTScrip™ mRNA-Human ALG14, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALG14
GTTS-WK25136MR IVTScrip™ mRNA-Human ATAD2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ATAD2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW